Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results
Niagen Bioscience reported Q2 net income of $1.0 million ($0.01 EPS) on sales of $29.8 million, with gross margin holding at 64.8%. The company executed $2.8 million in share buybacks and ended the quarter with $66.7 million in cash, while simultaneously launching the Niagen Plus telehealth platform.
Key figures
- Eps
- 0.01
- Revenue
- 29800000
- Guidance
- FY2026 e-commerce growth 10% to 15%; ingredient business expected to be lower YoY
- Adj ebitda
- 3000000
- Gross margin
- 64.8%
- Cash equivalents
- 66700000
- Share repurchase
- 2800000
- Operating cash flow ytd
- 1600000
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.